Bio-Techne to Present Innovative Gene Therapy Solutions Soon
Bio-Techne Showcases Revolutionary Solutions at ASGCT
Bio-Techne Corporation (NASDAQ: TECH) is preparing to highlight its cutting-edge advancements in spatial biology and cell and gene therapy workflow solutions at the American Society of Gene & Cell Therapy 2025 meeting. Set to occur in a vibrant city, Bio-Techne's presence at this prominent event demonstrates its commitment to leading the way in innovative healthcare solutions. Visitors can anticipate numerous products and technologies designed to enhance research and clinical outcomes.
Innovative Offerings at the Exhibition
At booth 1537, Bio-Techne will unveil its new RNAscope™ protease-free workflow that allows for the precise visualization of biodistribution of AAV vectors and various RNAs. This technology also covers important functional RNA and protein markers which are critical for examining gene expression and functionality.
The company will also showcase ProPak™ GMP cytokines, housed in single-use bags that optimize dosage and conform to closed-system manufacturing protocols essential for cell therapies. Furthermore, attendees will be introduced to the next-generation Simple Western Leo™ System, capable of processing up to 100 samples within just three hours, accelerating research efficiency.
Expert Presentations and Discussions
The conference will feature a variety of expert talks, prominently including contributions from leading researchers alongside Maithreyan Srinivasan, PhD, the Chief Scientific Officer at Advanced Cell Diagnostics, a Bio-Techne brand. The symposium on May 14 will center on the innovations of RNAscope technology, focusing on versatile applications including AAV, small RNA, and CAR-T cell therapies.
Focused Session Highlights
One of the invited guest speakers, Adrian Veres, MD, PhD, will present vital research on AI-designed AAV capsids aimed at enhanced gene delivery. Furthermore, William Salomon, PhD, will discuss his findings on visualizing RNA Gene Writer's activity in murine models, which showcases the potential of gene therapies for treating monogenic diseases.
On May 15, a moderated discussion led by Edward Pavina from Bio-Techne will address protein quantification methods vital to advancing gene therapy. This session features Julyana Acevedo, PhD, and Nicolas Tricaud, PhD, both of whom will discuss the analytical development related to gene therapy innovations.
The Vision of Bio-Techne
Kim Kelderman, President and CEO of Bio-Techne, remarked on the company's pivotal role in the gene and cell therapy sectors. With dedication to creating state-of-the-art tools for scientists and researchers, Bio-Techne is committed to advancing the landscape of therapeutic development. By enabling enhanced capabilities within ice-breaking scientific realms, the company is paving the path for safe treatments addressing various disorders.
This event not only celebrates existing technological advancements but also posits future techniques that strive to benefit both research and patient outcomes at large. Bio-Techne's extensive portfolio and unwavering vision for innovation ensure it remains at the forefront of the life sciences industry.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) operates as a global life sciences powerhouse, propelling scientific research with a broad range of innovative products and bioactive reagents catered to both research and clinical diagnostic communities. With a remarkable portfolio that includes numerous sophisticated tools, Bio-Techne plays a crucial role in aiding studies of biological processes and the progression of diseases.
Recently, the company reported a remarkable net revenue of approximately $1.2 billion, showcasing its commitment to innovation and quality. Employing around 3,100 professionals worldwide, Bio-Techne fosters a culture of excellence and continuous improvement, positioning itself as a leader in the global market.
Frequently Asked Questions
1. What will Bio-Techne present at the ASGCT conference?
Bio-Techne will showcase its advanced spatial biology technologies, including RNAscope™ workflows and innovative solutions for cell and gene therapy.
2. Who are the key speakers at the Bio-Techne symposium?
Leading researchers such as Maithreyan Srinivasan, MD, along with experts from various fields will present during the event.
3. What is the Simple Western Leo™ System?
This new system enhances research by allowing simultaneous processing of several samples, significantly improving workflow efficiency.
4. How does Bio-Techne support gene therapy development?
Bio-Techne provides innovative tools and technologies essential for cell therapy workflows and the overall advancement of gene therapy.
5. What is the significance of the RNAscope technology?
RNAscope technology allows for visualization of RNA markers, which is critical for understanding gene expression and its functionalities.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
